EMD-22852

Single-particle
9.9 Å
EMD-22852 Deposition: 13/10/2020
Map released: 28/04/2021
Last modified: 28/04/2021
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links

EMD-22852

Ebola virus GP (mucin deleted, Makona strain) bound to antibody Fab EBOV-237 and EBOV-515

EMD-22852

Single-particle
9.9 Å
EMD-22852 Deposition: 13/10/2020
Map released: 28/04/2021
Last modified: 28/04/2021
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Sample Organism: Ebola virus, Homo sapiens
Sample: Ebola virus GP (mucin deleted, Makona strain) bound to antibody Fab EBOV-237 and EBOV-515

Deposition Authors: Murin CD, Ward AB
Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies.
PUBMED: 33852862
DOI: doi:10.1016/j.celrep.2021.108984
ISSN: 2211-1247
Abstract:
Antibodies that target the glycan cap epitope on the ebolavirus glycoprotein (GP) are common in the adaptive response of survivors. A subset is known to be broadly neutralizing, but the details of their epitopes and basis for neutralization are not well understood. Here, we present cryoelectron microscopy (cryo-EM) structures of diverse glycan cap antibodies that variably synergize with GP base-binding antibodies. These structures describe a conserved site of vulnerability that anchors the mucin-like domains (MLDs) to the glycan cap, which we call the MLD anchor and cradle. Antibodies that bind to the MLD cradle share common features, including use of IGHV1-69 and IGHJ6 germline genes, which exploit hydrophobic residues and form β-hairpin structures to mimic the MLD anchor, disrupt MLD attachment, destabilize GP quaternary structure, and block cleavage events required for receptor binding. Our results provide a molecular basis for ebolavirus neutralization by broadly reactive glycan cap antibodies.